 |
197 Diseases |  |
398 Trials |
|
398 Trials |  |
21826 News |  |
| «12...255256257258259260261262263264265266267» |
- Yervoy (ipilimumab) / Ono Pharma, BMS
New P1 trial, Combination therapy, Metastases: Ipilimumab and Lenalidomide in Advanced Cancer (clinicaltrials.gov) - Dec 13, 2012
P1, N=101, Recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| lirilumab (BMS-986015) / Innate, BMS, Ono Pharma, Yervoy (ipilimumab) / BMS
New P1 trial, Combination therapy, Metastases: Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor (clinicaltrials.gov) - Dec 13, 2012
P1, N=125, Recruiting, Sponsor: Bristol-Myers Squibb
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment closed, Metastases: Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) (clinicaltrials.gov) - Dec 13, 2012
P1, N=50, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting
- GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Yervoy (ipilimumab) / BMS
Trial completion, Combination therapy, Tumor cell, Metastases: Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 13, 2012
P1, N=30, Completed, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| epacadostat (INCB024360) / Incyte
Enrollment open, Combination therapy, Metastases: A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - Dec 12, 2012
P1/2, N=136, Recruiting, Sponsor: Incyte Corporation
Active, not recruiting --> Completed Active, not recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Yervoy (ipilimumab) / BMS
New P1/2 trial, Metastases: Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma (clinicaltrials.gov) - Dec 4, 2012
P1/2, N=24, Completed, Sponsor: California Pacific Medical Center Research Institute
- ||||| Imlygic (talimogene laherparepvec) / Amgen
New P1/2 trial: Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (clinicaltrials.gov) - Dec 2, 2012
P1/2, N=149, Recruiting, Sponsor: Amgen
- | cyclophosphamide / Generic mfg.
New P2 trial, Metastases: CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma (clinicaltrials.gov) - Nov 28, 2012
P2, N=29, Active, not recruiting, Sponsor: Bhardwaj, Nina, M.D.
- Yervoy (ipilimumab) / BMS
New P1 trial, Metastases: Ipilimumab and Imatinib Mesylate in Advanced Cancer (clinicaltrials.gov) - Nov 28, 2012
P1, N=96, Recruiting, Sponsor: M.D. Anderson Cancer Center
- |||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment open, PD(L)-1 Biomarker: Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma (clinicaltrials.gov) - Nov 28, 2012
P1/2, N=141, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
New P1 trial, Combination therapy: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Nov 18, 2012
P1, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Yervoy (ipilimumab) / BMS
Trial initiation date, Metastases: Study of Immunotherapy to Treat Advanced Prostate Cancer (clinicaltrials.gov) - Nov 6, 2012
P3, N=800, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Initiation date: Oct 1911 --> May 2009
- ||||| Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer (clinicaltrials.gov) - Nov 6, 2012
P3, N=600, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Oct 1911 --> May 2009 Recruiting --> Active, not recruiting
- ||||| Yervoy (ipilimumab) / BMS
Enrollment closed, Metastases: Study of Immunotherapy to Treat Advanced Prostate Cancer (clinicaltrials.gov) - Nov 6, 2012
P3, N=800, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: Doxycycline, Temozolomide and Ipilimumab in Melanoma (clinicaltrials.gov) - Nov 5, 2012
P1/2, N=58, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma (clinicaltrials.gov) - Oct 25, 2012
P2, N=26, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| lirilumab (BMS-986015) / Innate, BMS, Ono Pharma, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial: A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 24, 2012
P1, N=162, Recruiting, Sponsor: Bristol-Myers Squibb
- ||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Enrollment open, Monotherapy, PD(L)-1 Biomarker, IO biomarker: CheckMate 038: PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (clinicaltrials.gov) - Oct 21, 2012
P1, N=160, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
New P1 trial: Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer (clinicaltrials.gov) - Oct 18, 2012
P1, N=18, Recruiting, Sponsor: National Cancer Institute (NCI)
- ||||| Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma (clinicaltrials.gov) - Oct 16, 2012
P2, N=138, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- | Intron A (interferon ?-2b) / Merck (MSD), Biogen, Yervoy (ipilimumab) / BMS
New P2 trial, Combination therapy, Surgery, Metastases: E3611: Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 15, 2012
P2, N=88, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Yervoy (ipilimumab) / BMS
New P1 trial, Surgery: Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma (clinicaltrials.gov) - Oct 8, 2012
P1, N=24, Recruiting, Sponsor: Thomas Jefferson University
- Yervoy (ipilimumab) / BMS
Metastases: Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts (clinicaltrials.gov) - Oct 3, 2012
P=N/A, N=10, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Yervoy (ipilimumab) / BMS
Enrollment open, Metastases: A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 (clinicaltrials.gov) - Oct 1, 2012
P2, N=41, Recruiting, Sponsor: University Hospital Tuebingen
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma (clinicaltrials.gov) - Sep 26, 2012
P2, N=40, Ongoing, Sponsor: Bristol-Myers Squibb International Corporation
- Yervoy (ipilimumab) / BMS
New P2 trial: Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer (clinicaltrials.gov) - Sep 24, 2012
P2, N=44, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma (clinicaltrials.gov) - Sep 19, 2012
P2, N=100, Recruiting, Sponsor: New York University School of Medicine
- Yervoy (ipilimumab) / Ono Pharma, BMS
New P1/2 trial, Metastases: Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma (clinicaltrials.gov) - Sep 19, 2012
P1/2, N=0, Withdrawn, Sponsor: Ludwig Institute for Cancer Research
- Yervoy (ipilimumab) / BMS
New P1/2 trial: Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na (clinicaltrials.gov) - Sep 18, 2012
P1/2, N=25, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- ||| Opdivo (nivolumab) / BMS
Monotherapy, PD(L)-1 Biomarker, IO biomarker: CheckMate 039: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (clinicaltrials.gov) - Sep 18, 2012
P1, N=180, Recruiting, Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
Enrollment closed, Pan tumor, Metastases: DeCOG: THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease (clinicaltrials.gov) - Sep 16, 2012
P2, N=41, Active, not recruiting, Sponsor: Prof. Dr. med. Dirk Schadendorf
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma (clinicaltrials.gov) - Sep 5, 2012
P2, N=26, Recruiting, Sponsor: Bristol-Myers Squibb
- Yervoy (ipilimumab) / BMS
New P2 trial, Combination therapy, Metastases: Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma (clinicaltrials.gov) - Aug 29, 2012
P2, N=30, Active, not recruiting, Sponsor: Jewish General Hospital
- | Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma (clinicaltrials.gov) - Aug 26, 2012
P2, N=45, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- | Yervoy (ipilimumab) / BMS
Enrollment open, Monotherapy: Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer (clinicaltrials.gov) - Aug 23, 2012
P2, N=40, Recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / Ono Pharma, BMS
New P1 trial: A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma (clinicaltrials.gov) - Aug 22, 2012
P1, N=18, Active, not recruiting, Sponsor: University of Utah
- Yervoy (ipilimumab) / Ono Pharma, BMS
Trial initiation date, Metastases: Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma (clinicaltrials.gov) - Aug 19, 2012
P2, N=50, Recruiting, Sponsor: Wolfram Samlowski
Not yet recruiting --> Recruiting Initiation date: Apr 2012 --> Aug 2012
- Yervoy (ipilimumab) / Ono Pharma, BMS
Enrollment open, Metastases: Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma (clinicaltrials.gov) - Aug 19, 2012
P2, N=50, Recruiting, Sponsor: Wolfram Samlowski
Initiation date: Apr 2012 --> Aug 2012 Not yet recruiting --> Recruiting
- TriMix-DC (ex-vivo autologous dendritic cells vaccine) / eTheRNA immunotherapies, Yervoy (ipilimumab) / BMS
Enrollment closed, Combination therapy: TriMix-Ipi: Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (clinicaltrials.gov) - Aug 15, 2012
P2, N=39, Active, not recruiting, Sponsor: Bart Neyns
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Yervoy (ipilimumab) / BMS
Enrollment closed: Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma (clinicaltrials.gov) - Aug 7, 2012
P1, N=46, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| Muphoran (fotemustine) / Servier, Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: NIBIT-M1: A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma (clinicaltrials.gov) - Jul 30, 2012
P2, N=86, Active, not recruiting, Sponsor: Italian Network for Tumor Biotherapy
- Yervoy (ipilimumab) / BMS
Enrollment open, Combination therapy, Surgery, Stroma, Metastases: Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic (clinicaltrials.gov) - Jul 29, 2012
P1, N=39, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Yervoy (ipilimumab) / BMS
New P1 trial, Combination therapy, Surgery, Stroma, Metastases: Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic (clinicaltrials.gov) - Jul 16, 2012
P1, N=39, Recruiting, Sponsor: National Cancer Institute (NCI)
- | Yervoy (ipilimumab) / BMS
New P2 trial, Monotherapy: Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer (clinicaltrials.gov) - Jun 3, 2012
P2, N=40, Recruiting, Sponsor: Bristol-Myers Squibb
- ||||| epacadostat (INCB024360) / Incyte
New P1/2 trial, Combination therapy, Metastases: A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (clinicaltrials.gov) - May 22, 2012
P1/2, N=136, Recruiting, Sponsor: Incyte Corporation
- ||| Opdivo (nivolumab) / BMS
Monotherapy, PD(L)-1 Biomarker, IO biomarker: CheckMate 039: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (clinicaltrials.gov) - May 3, 2012
P1, N=180, Recruiting, Sponsor: Bristol-Myers Squibb
- | Yervoy (ipilimumab) / BMS
New P1/2 trial, Metastases: Doxycycline, Temozolomide and Ipilimumab in Melanoma (clinicaltrials.gov) - Apr 30, 2012
P1/2, N=58, Recruiting, Sponsor: M.D. Anderson Cancer Center
- | Yervoy (ipilimumab) / BMS
New P2 trial, Metastases: An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy (clinicaltrials.gov) - Apr 24, 2012
P2, N=114, Active, not recruiting, Sponsor: Bristol-Myers Squibb
- ||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
New P1/2 trial, PD(L)-1 Biomarker: Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma (clinicaltrials.gov) - Apr 23, 2012
P1/2, N=141, Recruiting, Sponsor: M.D. Anderson Cancer Center
- Yervoy (ipilimumab) / Ono Pharma, BMS
New P2 trial, Metastases: Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma (clinicaltrials.gov) - Mar 27, 2012
P2, N=50, Recruiting, Sponsor: Wolfram Samlowski